A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
Barrett, Doreen, Bilic, Sanela, Chyung, Yung, Cote, Shaun M., Iarrobino, Ryan, Kacena, Katherine, Kalra, Ashish, Long, Kimberly, Nomikos, George, Place, Amy, Still, James Gordon, Vrishabhendra, Leela
Published in Advances in therapy (01.06.2021)
Published in Advances in therapy (01.06.2021)
Get full text
Journal Article
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study
Crawford, Thomas O, Darras, Basil T, Day, John W, Dunaway Young, Sally, Duong, Tina, Nelson, Leslie L, Barrett, Doreen, Song, Guochen, Bilic, Sanela, Cote, Shaun, Sadanowicz, Mara, Iarrobino, Ryan, Xu, Tiina J, O'Neil, Janet, Rossello, José, Place, Amy, Kertesz, Nathalie, Nomikos, George, Chyung, Yung
Published in Neurology (12.03.2024)
Published in Neurology (12.03.2024)
Get more information
Journal Article
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study
Published in Neurology
(09.07.2024)
Get more information
Journal Article
Relationship of pharmacokinetics and pharmacodynamics to apitegromab efficacy in patients with later-onset spinal muscular atrophy (Types 2 and 3 SMA): Results from the TOPAZ study
Crawford, Thomas, Place, Amy, Barrett, Doreen, Cote, Shaun, Nomikos, George, Song, Guochen, Bilic, Sanela, Kalra, Ashish, Sadanowicz, Mara, O'Neil, Janet, Iarrobino, Ryan, Kertesz, Nathalie, Chyung, Yung
Published in Journal of the neurological sciences (01.10.2021)
Published in Journal of the neurological sciences (01.10.2021)
Get full text
Journal Article